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Abstract
Objective
Long-term treatment with thiopurines is associated with a decreased risk of Crohn’s disease
(CD) flare but an increased risk of various cancers depending on gender, age, and pres-
ence of extensive colitis. We evaluated risks and benefits of withdrawing thiopurines in
patients with CD in prolonged remission.
Methods
We developed a Markov model assessing risks and benefits of withdrawing thiopurines
compared to continuing thiopurines in a lifetime horizon. The model was stratified by age
(35 and 65 years old at thiopurine withdrawal), gender and presence of extensive colitis.
Parameter estimates were taken from French cohorts and hospital databases, cancer and
death national registries and published literature. Life expectancy, rates of relapse, serious
adverse events, and causes-of-death were evaluated.
Results
In patients without extensive colitis, continuing thiopurines increased life expectancy up to
0.03 years for 35 year-old men and women but decreased life expectancy down to 0.07
years for 65 year-old men and women. Withdrawal strategy became the preferred strategy
at 40.6 years for men, and 45.7 years for women without extensive colitis. In patients with
extensive colitis, continuation strategy was the preferred strategy regardless of age. Risk-
benefit analysis was not modified by duration of CD activity.
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Conclusions
Factors determining life expectancy associated with withdrawal or continuation of thiopurines
in patients with CD and in sustained clinical remission vary substantially according to gender,
age and presence of extensive colitis. Individual decisions to continue or withdraw thiopurines
in patients with CD in sustained remission should take into account these parameters.
Introduction
Crohn’s disease (CD) is a chronic idiopathic inflammatory bowel disease with relapsing and
remitting episodes that may lead to irreversible intestinal lesions, severe disability, and excess
mortality.[1–3] Thiopurines include azathioprine and its metabolite 6-mercaptopurine. These
two immunosuppressive drugs (thiopurines) have been shown to be superior to placebo for
inducing and maintaining clinical remission of CD: about five CD patients need to be continu-
ously treated with thiopurines to prevent one relapsing episode.[4] Thiopurines are currently
recommended as first-line maintenance therapy in various clinical situations within the first
year of CD onset,[5] and the prevalence of CD patients exposed to prolonged immunosuppres-
sive treatment is increasing, e.g., about 40% in France in 2006.[6]
Prolonged treatment with thiopurines may be associated with excess mortality risks due to
opportunistic viral infections[7,8] and lymphoma.[6] In addition, second-line maintenance
therapy with tumor necrosis factors inhibitors (anti-TNFs) is associated with excess mortality
risks of prolonged immunosuppressive treatment.[9] In a recent survey, about 60% of patients
on maintenance therapy reported that they were concerned by serious adverse events (SAE)
and engaged intentionally in a non-adherent behavior,[10] whereas another recent survey con-
clude that patient may accept high risk levels of lymphoma and serious infection to maintain
disease remission.[11] Risk-benefit assessment of medications is therefore strongly needed to
provide relevant information to patients.
In the present study, we developed a model-based risk-benefit analysis of withdrawing thio-
purines in CD patients in prolonged remission. The model makes explicit the trade-off between
two excess mortality risks regarding life expectancy: 1) withdrawing thiopurines increases the
cumulative rate of severe relapse over time as compared to continuing thiopurines; 2) continu-
ing thiopurines increases the risks of serious adverse events including a sharp increase of can-
cer-related risks with age and serious infections. Because of two main characteristics of CD
patients regarding excess mortality risks, we conducted threshold analyses on age stratified by
gender and presence of extensive colitis.[12] Finally, extensive sensitivity analyses were
performed.
Materials and Methods
We developed a decision-analytic Markov model that follows cohorts of CD patients in pro-
longed remission stratified by age, gender and presence of extensive colitis (as defined by a pro-
portion of the colonic mucosal area macroscopically or microscopically affected by
disease>50%).[12] We used the model to identify the lifetime risks and benefits of withdrawing
thiopurines, providing practical insights relevant for the management of CD.
Decision Tree and Markov Model
The Markov model simulates the natural history of CD with relapsing and remitting episodes
(Fig 1). The target population is initially under thiopurines since the first year of CD onset and
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set in prolonged remission since four years with thiopurines, for a total of 5 years under thio-
purines. In the base-case scenario, we assumed that chronic bowel inflammation will remain
active for 15 years after cohort entry and incur a baseline risk of relapse every year. Patients
remaining in remission or developing a mild relapse continue on the same maintenance ther-
apy at the next Markov cycle. Patients developing a severe relapse are hospitalized with an
excess mortality risk depending on the need for surgery. In case of intestinal resection, we
assumed that the baseline risk of relapse decreases for two years.[13] In all patients surviving
severe relapse, maintenance therapy is changed at the next Markov cycle. After 15 years,
patients are no longer at risk of relapse and resume to the life expectancy of the general popula-
tion. We assumed that maintenance therapy is stopped in patients without CD activity.
We compared two alternative strategies: withdrawing (strategy W) versus continuing (strat-
egy C) maintenance therapy with thiopurines (Fig 2). A clinical trial did not show the noninfer-
iority of withdrawing compared to continuing maintenance therapy regarding the relapse rate
at 18 months,[14] and the relapse rate became significantly higher at 5 years.[15] We assumed
Fig 1. Events related to Crohn’s disease and treatment and associated with mortality risk.
doi:10.1371/journal.pone.0157191.g001
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conservatively that strategy W increases the baseline risk of relapse from the first Markov cycle
onwards. Patients who relapse after discontinuation of thiopurines are treated with a second
course of thiopurines, and we assumed that remission is achieved in all patients who previously
respond to thiopurines.[15] However, we assumed conservatively that those patients back on
maintenance therapy with thiopurines would not resume to the baseline risk of relapse of strat-
egy C.
Once on maintenance therapy with thiopurines, all patients of strategies C andW receive
the same standard of care over time depending on the occurrence of a severe relapse or SAE.
Severe relapse is followed at the next Markov cycle by a gradual response with several lines of
maintenance therapy involving Anti-TNFs. We assumed that no other Anti-TNFs than inflixi-
mab and adalimumab would be available, and only steroids would be administered in patients
having failed all lines of maintenance therapy. The doses of each Anti-TNFs are systematically
intensified before discontinuation, except if treatment failed at induction therapy (i.e., primary
non-response) or SAE occurred.
In the base-case scenario, we considered 4 SAE as defined by an excess mortality risk (Fig
1). Patients exposed to all immunosuppressive drugs may develop severe opportunistic infec-
tions: immunosuppressive drugs are temporally stopped for six months on average and then
resumed. Patients exposed to immunosuppressive drugs are at increased risk of lymphoma
(thiopurines) and melanoma skin cancer (Anti-TNFs), but at decreased risk of colorectal can-
cer (CRC) in presence of extensive colitis (thiopurines). In patients diagnosed with cancer, we
assumed that patients were mostly at risk of specific mortality from cancer for 5 years. Mainte-
nance therapy was discontinued in all cancer patients, but steroids may be used in cancer survi-
vors resuming to CD activity and relapsing. Lastly, patients under thiopurines may present
non melanoma skin cancer (non-MSC) leading to withdrawal of thiopurines and monotherapy
of Anti-TNFs if required. In sensitivity analyses, we introduced other SAE recently attributed
to thiopurines: acute myeloid leukemia;[16] urinary tract cancer;[17] and bone marrow sup-
pression.[18]
The model was implemented in TreeAge Pro 2011 (Williamstown, MA).
Fig 2. Overview of the Decision Model: therapeutic management.
doi:10.1371/journal.pone.0157191.g002
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Data and Sources
We estimated model parameters from French hospital Diagnosis Related Groups (DRGs) data-
base (Programme de médicalisation des systèmes d’information (PMSI)),[19] the French can-
cer and death national registries,[20–24] the CESAME cohort,[25] the Saint-Antoine hospital
IBD registry (MICISTA registry), and from the literature otherwise [4,14,26–42] (Table 1). The
study was approved by the French National Commission for Data Protection (CNIL DE-2013-
068). The requirement for informed consent was waived because the study used de-identified
data.
Target population characteristics. Baseline characteristics of the overall population of
CD patients in prolonged remission were estimated from the French National Hospital DRG
database (PMSI). About 34,730 adult patients were hospitalized with a primary diagnosis of
CD in 2008–2009 (ICD-10 medical code: K50). The proportion of female was 60%, and age
had a lognormal distribution with a mean (median) age of 40 (38) years old. The proportion of
CD patients with extensive colitis (39.0%) was estimated from the CESAME cohort.[25]
Natural history of CD. The annual risk of relapse on maintenance therapy was estimated
from clinical trials or large cohorts of CD patients (Table 1). The relative risk of relapse of
withdrawing thiopurines was estimated from two clinical trials conducted in CD patients in
prolonged remission for more than 2[26] and 3.5[14] years. The proportion of patients hospi-
talized for a severe relapse (29.0%), and among them, the proportion of patients undergoing
surgery (37.9%) were estimated from 357 CD patients having received thiopurines for at least 3
years with a complete follow-up in the Saint-Antoine hospital CD registry (MICISTA). The
proportion of patients undergoing surgery and having an intestinal resection (72.4%) was esti-
mated from the Olmsted Cohort Study.[37]
Excess mortality risks due to severe relapse were estimated from the French National Hospi-
tal DRG database (PMSI). Among CD patients aged 25 to 80 years old, 42,264 hospital stays
for a severe relapse were selected in 2008–2009. In-hospital mortality rates were significantly
increased with surgery and an older age, but not gender.
Serious adverse events of prolonged immunosuppressive treatment. The frequency of
opportunistic infections was measured from the French National Hospital DRG database
(PMSI). Among CD patients aged 25 to 80 years old without cancer or HIV infection, 70 primary
diagnoses of opportunistic viral infection were attributed to thiopurines in the absence of hospital
records of Anti-TNFs (3 patients died: 1 herpes simplex virus, 1 cytomegalovirus, 1 varicella-zos-
ter virus), and 87 primary diagnoses of opportunistic infection were otherwise attributed to Anti-
TNFs (4 patients died: 1 aspergillosis, 1 candidemia, 1 pneumocystis, 1 cytomegalovirus). Drug
exposure to Anti-TNFs was directly measured from hospital records in 2008–2009 (7,709
patient-years) and indirectly estimated for thiopurines with use of the proportion of CD patients
treated in the CESAME cohort (40,579 patient-years). Other risks of SAE due to Anti-TNFs and
requiring drugs discontinuation were estimated from the literature.[38,39]
The annual risk of cancer was calculated as the product of the age- and gender-specific inci-
dence rate observed in French cancer registries (S1 Table),[20,21] and the standardized inci-
dence ratio (SIR) with immunosuppressant drug exposure. We obtained SIR according to our
predefined sequence for use of drugs and drug combinations from meta-analyses (Table 1).
[25,40–42] In case of lymphoma occurrence, we assumed that 90% of patients develop non-
Hodgkin’s lymphoma (NHL) of higher age-specific incidence and mortality rates as compared
to Hodgkin’s lymphoma. Five-year relative mortality rates were obtained by age and gender
from the French cancer registries (S2 Table).[22,23]
Cohorts of CD patients were further stratified by the presence of extensive colitis. In a recent
study, CD patients with extensive colitis for more than 10 years had a higher risk of colorectal
Withdrawing Thiopurines in Crohn’s Disease
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Table 1. Model parameter values.
Model parameter Base Min Max Source
Target population characteristics
Female (%) 60 - -
Cohort starting age, years 35 25 65
Duration of Crohn's disease activity, years 20 20 55
Extensive colitis (%) 39 - - 25
Annual risk of relapse
Before intestinal resection
Thiopurines continued 0.093 0.015 0.170 14, 26
Relative Risk of relapse when withdrawing thiopurines versus continuing 2.793 2.185 9.549 14, 26
Thiopurines resumed after withdrawal 0.358 0.243 0.473 4
Thiopurines and Inﬂiximab 0.348 0.291 0.405 27
Inﬂiximab monotherapy 0.537 0.483 0.592 27
Inﬂiximab optimized and thiopurines 0.518 0.425 0.610 28
Inﬂiximab optimized monotherapy 0.532 0.389 0.675 28
Primary non-response to Inﬂiximab 0.092 0.066 0.118 30
Thiopurines and Adalimumab 0.570 0.468 0.673 30
Adalimumab monotherapy 0.574 0.530 0.619 30
Adalimumab after optimization (with or without thiopurines) 0.528 0.365 0.691 31, Expert opinion
Primary non-response to Adalimumab 0.041 0.023 0.060 32
Steroids only for induction of remission 0.402 0.318 0.485 33
After intestinal resection
Thiopurines 0.157 0.106 0.207 34
Inﬂiximab (without or with thiopurines) 0.01 0 0.05 35
Adalimumab (without or with thiopurines) 0.065 0 0.185 36
Relapse-related events
Severe relapse 0.290 0.20 0.38 MICISTA Cohort
Surgery for severe relapse 0.379 0.20 0.56 MICISTA Cohort
Intestinal resection for surgery 0.724 0.50 1.00 37
Duration of decreased risk of relapse after intestinal resection (years) 2 1 5 Expert opinion
Annual risk of Serious Adverse Events
Neutropenia with thiopurines 0.0015 0.0012 0.0019 French DRG 2008–09
Opportunistic (viral) infection with thiopurines 0.0017 0.0013 0.0022 French DRG 2008–09
Opportunistic infection with anti-TNF drugs 0.0113 0.0090 0.0139 French DRG 2008–09
SAE due to inﬂiximab (opportunistic infections and cancers excluded) 0.018 0.013 0.022 38
SAE due to adalimumab (opportunistic infections and cancers excluded) 0.001 0 0.003 39
Standardized Incidence Ratio of Lymphoma
Thiopurines continuation 4.92 3.10 7.78 40
Standardized Incidence Ratio of Colorectal cancer
Longstanding colitis 9.04 4.81 15.5 25
Longstanding colitis, Thiopurines continuation 0.28 0.09 0.89 25
Standardized Incidence Ratio of melanoma skin cancer (MSC)
Anti-TNF continuation 1.37 1.10 1.70 40
Standardized Incidence Ratio of non-melanoma skin cancer (non-MSC)
Thiopurines continuation 2.28 1.50 3.45 42
Standardized Incidence Ratio of acute myeloid leukemia
Thiopurines continuation 6.98 1.44 20.36 16
(Continued)
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cancer than other CD patients, but maintenance therapy with thiopurines was found protec-
tive.[25] CD patients without extensive colitis have the same risk of colorectal cancer than the
general population.[25,43]
Background (competing) mortality. Competing mortality was derived from 2010 French
life tables after exclusion of all causes-of-death explored in the model (S3 Table).
Risk-Benefit Analysis
The primary outcome of the risk-benefit analysis was life expectancy. Secondary outcomes
included the probability of severe relapse with and without surgery, opportunistic infection,
lymphoma, colorectal cancer, melanoma skin cancer, and causes-of-deaths. Probabilities were
calculated over the duration of CD activity for CD-related events and over lifetime otherwise.
In addition, we measured quality-adjusted life years (QALYs) with use of published utility esti-
mates for each health state of the model (S4 Table).
In the first step of the risk-benefit analysis, we conducted deterministic analyses for patients
aged 35 and 65 years old at the decision, stratified by gender and presence of extensive colitis.
35 years old correspond to 5 years after the mean age of CD onset [3] and 65 years old is a clas-
sic threshold for increase of SAE. Then, we conducted threshold analyses on age to assess when
strategy W decreased life expectancy.
Secondly, the robustness of study results was assessed by relaxing key assumptions of the
model regarding: 1) better effectiveness of strategy W (i.e., at withdrawal and when thiopurines
are resumed; 2) lower protective effect of thiopurines on colorectal cancer and lower relative
risk of colorectal cancer in case of extensive colitis); 3) the addition of other SAE (myelotoxi-
city, acute myeloid leukemia, urinary tract cancer); 4) longer duration of CD activity.
Finally, we performed a probabilistic sensitivity analysis to assess to what extent withdraw-
ing thiopurines may be an acceptable strategy overall. We conducted Monte Carlo simulations
of 10, 000 CD cohorts incorporating all uncertainties from variables distributions derived from
the literature (S5 Table) and measured how frequently strategy W decreased life expectancy as
compared to strategy C.
Results
Stratified deterministic analyses
Life expectancy and causes of death from continuing or withdrawing maintenance therapy
with thiopurines in cohorts without extensive colitis are provided in Table 2. In 35 year-old
Table 1. (Continued)
Model parameter Base Min Max Source
Standardized Incidence Ratio of urinary tract cancer
Thiopurines continuation 3.40 1.47 6.71 17
Mortality rates of Severe Adverse Events
Neutropenia with thiopurines 0.0328 0.0040 0.1135 French DRG 2008–09
Opportunistic infection with thiopurines 0.0286 0.0035 0.0994 French DRG 2008–09
Opportunistic infection with anti-TNF drugs 0.0460 0.0127 0.1136 French DRG 2008–09
Age-adjusted mortality rate of severe ﬂare without surgery 0.0021 0.0011 0.0036 French DRG 2008–09
Age-adjusted mortality rate of severe ﬂare with surgery 0.0103 0.0056 0.0177 French DRG 2008–09
Min and Max were computed from exact 95% conﬁdence intervals of percentages.
doi:10.1371/journal.pone.0157191.t001
Withdrawing Thiopurines in Crohn’s Disease
PLOS ONE | DOI:10.1371/journal.pone.0157191 June 6, 2016 7 / 15
patients without extensive colitis, continuing thiopurines increased life expectancy of all
patients in prolonged remission. In 35 year-old men without extensive colitis, continuing thio-
purines reduced deaths related to severe relapse by half (0.31% versus 0.64%), although deaths
related to SAE increased by 17%. Similar results were found in 35 year-old women without
extensive colitis. In 65 year-old patients without extensive colitis, withdrawing thiopurines
increased life expectancy for men and women. As compared to 35 year-old patients, decision
reversal was related to lower rates of death caused by severe relapse and higher rates of death
caused by SAE. In CD patients in prolonged remission without extensive colitis, withdrawing
thiopurines increased life expectancy after 40.6 years in men and 45.7 years in women (Fig 3).
Events rates associated with continuing or withdrawing thiopurines are shown in Table 3.
In 35 year-old men without extensive colitis, continuing thiopurines increased lifetime risks for
lymphoma by 18% and decreased lifetime risks for severe flare by 52%. In 65 year-old men
without extensive colitis, continuing thiopurines increased lifetime risks for lymphoma by
77%. Similar results were found in women.
Life expectancy and causes of death from continuing or withdrawing maintenance therapy
with thiopurines in cohorts with extensive colitis are provided in S6 Table. In 35 year-old
patients with extensive colitis, continuing thiopurines increased life expectancy for men and
women. In contrast to 65 year-old patients without extensive colitis, continuing thiopurines
still increased life expectancy for 65 year-old men and women with extensive colitis. Continu-
ing thiopurines remained the preferred strategy in CD patients with extensive colitis regardless
of age (Fig 3). Events rates associated with continuing or withdrawing in cohorts with extensive
colitis are shown in S7 Table. In 35 year-old men with extensive colitis, continuing thiopurines
decreased lifetime risks for colorectal cancer by 10%. In 65 year-old men with extensive colitis,
continuing thiopurines decreased lifetime risks for colorectal cancer by 44%. Similar results
were found in women.
Sensitivity analysis
The study results were sensitive to a better effectiveness of thiopurines withdrawal as compared
to thiopurines continuation in patients without extensive colitis. If withdrawing thiopurines
Table 2. Life expectancy and causes-of-death from continuing (C) or withdrawing (W) maintenance therapy with thiopurines in stratified CD
cohorts without extensive colitis.
Male, 35y., CD still
active for 15y.
Male, 65y., CD still
active for 15y.
Female, 35y., CD
still active for 15y.
Female, 65y., CD
still active for 15y.
C W C W C W C W
Life expectancy, age at death 73.99 73.97 79.54 79.61 79.86 79.83 82.97 83.02
Loss in life expectancy as compared
to general population, years
-0.25 -0.27 -0.18 -0.11 -0.28 -0.31 -0.17 -0.12
Causes of death, %
Severe relapse without surgery 0.08% 0.16% 0.07% 0.12% 0.08% 0.16% 0.07% 0.14%
Severe relapse with surgery 0.23% 0.48% 0.21% 0.37% 0.24% 0.49% 0.22% 0.42%
Opportunistic infection 0.18% 0.12% 0.17% 0.09% 0.19% 0.12% 0.18% 0.10%
Lymphoma 0.76% 0.67% 1.81% 1.01% 0.53% 0.48% 1.28% 0.72%
Colorectal cancer 1.90% 1.91% 1.61% 1.63% 1.49% 1.50% 1.21% 1.22%
Melanoma skin cancer 0.57% 0.21% 0.31% 0.17% 0.63% 0.18% 0.24% 0.12%
Other causes of death 96.28% 96.45% 95.82% 96.61% 96.84% 97.07% 96.80% 97.28%
Relapse 0.31% 0.64% 0.28% 0.49% 0.32% 0.65% 0.29% 0.56%
SAE 3.41% 2.91% 3.90% 2.90% 2.84% 2.28% 2.91% 2.16%
doi:10.1371/journal.pone.0157191.t002
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increased the relative risk of relapse below a threshold of 2.2, (base-case 2.79), withdrawing
thiopurines became the preferred strategy regardless of age (S1 Fig).
The base-case model was robust to variation up to the 95% confidence bounds of relative risk
of CRC in case of extensive colitis and hazard ratio for CRC between patients under thiopurines
and patients not receiving thiopurines (respectively 0.89 and 4.81). In a 3-way sensitivity analysis
including these values, continuing thiopurines remained the preferred strategy in 35 year-old
patients with extensive colitis. If we considered the relative risk of CRC in case of extensive colitis
at its lower limit of the 95% confidence interval (4.81, base-case 9.04) and the base-case hazard
ratio for CRC between patients under thiopurines and patients not receiving thiopurines, with-
drawal strategy remained the preferred strategy in 65 year-old patients with extensive colitis.
If QALYs based on published utility estimates were considered instead of life expectancy,
continuing thiopurines was the preferred strategy, regardless of gender, age, and presence of
extensive colitis (S6 Table). Complementary sensitivity analyses are detailed in supplementary
material (S1 Text).
Fig 3. One-way sensitivity analysis on cohort starting age. (Mean age increase at death associated to age increase at the time of decision is
related to shorter exposition to competing mortality risk)
doi:10.1371/journal.pone.0157191.g003
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Probabilistic analysis: simulation of 10, 000 CD cohorts
In the base-case scenario, continuing thiopurines increased life expectancy in 52.2% and 93.7%
of 10, 000 simulated cohorts of CD patients in prolonged remission respectively without and
with EC (Table 4); overall, continuing thiopurines incurred a gain of years as compared to thio-
purines withdrawal in CD patients without and with EC of 0.03 (CI 95%, -0.03; 0.14) and 0.19
(CI 95%, 0.06; 0.24), respectively.
Discussion
Our decision analytic model demonstrates that the impact on life expectancy of withdrawing
maintenance therapy with thiopurines in CD patients with prolonged remission depends on
gender, age, and presence of extensive colitis. It relates primarily on the increased risks of can-
cer with prolonged immunosuppressive treatment by age and gender.[22,23] In this era of
early and more aggressive treatment strategy, it remains important to study the impact of
treatment withdrawal due to possible safety concerns and drug costs constraints.[44] CD phe-
notype was also a determinant characteristic in the decision since the impact of thiopurines
therapy differs in patients with or without extensive colitis. The chemopreventive effect of thio-
purines on colorectal cancer remains controversial. A recent meta-analysis did not find a
Table 3. Events associated with continuing (C) or withdrawing (W) frommaintenance therapy with thiopurines in patients without extensive colitis.
Male, 35y., CD
still active for
15y.
Male, 65y., CD
still active for
15y.
Female, 35y., CD
still active for
15y.
Female, 65y., CD
still active for
15y.
C W C W C W C W
Events for 1,000 patients-years
Severe relapse (during CD activity) 40.64 84.99 46.05 80.68 41.15 85.25 43.85 82.67
Lymphoma 0.58 0.49 0.99 0.56 0.36 0.31 0.63 0.36
Colorectal cancer 1.47 1.48 1.10 1.11 1.02 1.03 0.76 0.77
Opportunistic infection (during drug exposure) 3.31 1.93 3.63 1.71 3.35 1.95 3.50 1.81
Relative risk between continuation and withdrawal
strategy
Severe relapse 0.48 0.57 0.48 0.53
Lymphoma 1.18 1.77 1.16 1.77
Colorectal cancer 1.00 0.99 0.99 0.99
Opportunistic infection 1.72 2.12 1.72 1.93
Relative risk compared to general population
Lymphoma 1.39 1.18 3.44 1.94 1.35 1.16 3.45 1.95
Colorectal cancer 0.99 1.00 0.98 0.99 0.99 1.00 0.99 0.99
doi:10.1371/journal.pone.0157191.t003
Table 4. Life expectancy from continuing (C) or withdrawing (W) maintenance therapy with thiopurines in 10,000 simulations of CD cohorts in pro-
longed remission.
CD patients without extensive colitis CD patients with extensive colitis
C 95% CI W 95% CI C 95% CI W 95% CI
Life expectancy, age at death, years 77.80 72.91 83.68 77.77 72.77 83.71 77.54 72.53 83.55 77.35 72.29 83.49
Loss in life expectancy as compared to general
population, years
-0.47 -0.66 -0.13 -0.50 -0.80 -0.10 -0.74 -1.04 -0.26 -0.93 -1.28 -0.32
Proportion of preferred strategy 52.2% 47.8% 93.7% 6.3%
doi:10.1371/journal.pone.0157191.t004
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chemopreventive effect of thiopurines on colorectal cancer in patients with IBD,[43] but a che-
mopreventive effect was suggested in presence of extensive colitis and IBD duration longer
than 10 years.[25] Similar findings were also described in a recent Spanish cohort.[45]
The originality of our study relies on the development of a decision model depicting real-life
treatment of CD.We included in the same model several treatment options that could influence
the risk of relapse: primary non response of Anti-TNFs; dose adjustment before switching to
another biological regimen; and different surgical procedures. One of the strengths of our model
is the source of the parameters. The relapse related outcomes and risks of opportunistic infections
were estimated from a large prospective cohort of CD patients (MICISTA) and the French
National Hospital DRG (PMSI) database with a total of 42,264 patients identified with CD.
In the base-case analysis, the difference in life expectancy was expectedly low because compet-
ing mortality was included in the model and the two strategies only differed by their first treat-
ment level. Patients received the same standard of care over time once on maintenance therapy
with thiopurines, whatever strategy C orW. Furthermore, we made conservative assumptions as
we assumed that patients under a second course of thiopurines in strategyW would not resume
to the baseline risk of relapse of strategy C. This assumption favors strategy C and explains much
higher rates of relapse over lifetime in strategyW. Conversely, it strengthens our results on the
lifetime benefits of withdrawing thiopurines for a subset of patients in clinical remission.
Our study has several limitations. We relied on life expectancy as the primary health out-
come. Accordingly, events without increased mortality risk were not taken into account in the
decision-analysis model. Alternatively, the “utility” associated with health states may have been
introduced to estimate gains in Quality-Adjusted Life Years (QALYs). However, we found vari-
ous utility estimates in the field of inflammatory bowel disease,[46] and preferred to rely on life
expectancy as primary health outcome.
The minor differences in life expectancy reported here were not clinically significant
(between 7 and 36 days according to base-case scenarios). However, we observed marked dif-
ferences in individual risks (related to CD activity and SAE) between therapeutic strategies
according to patient characteristics and IBD phenotype. These personalized data about risks
are of major importance when physicians inform their patients in a shared decision-making
about treatment continuation.
We assumed an optimal adherence rate assuming that model parameters estimated from
cohort studies incorporate real-life adherence. Furthermore, we considered clinical relapse
without considering biological parameters such as C-reactive protein (CRP) or fecal calprotec-
tin, because studies used for tabulating model parameters relied on the clinical assessment of
relapse. Future models should include parameters from studies assessing relapse on clinical
and biological parameters. Lastly, the sequential medical options included two biological
agents. Future models should be updated according future approved drugs.
In conclusion, this study shows that withdrawing thiopurines is the best strategy for a large
subset of patients in a simulated cohort of CD patients in clinical sustained remission regarding
benefits and associated risks related to immunosuppressant drugs. This decision depends on
gender, age, and disease location, as continuing thiopurines remains the best decision in case of
extensive colitis regardless age and gender. The decision on continuing or withdrawing thio-
purines for patients in sustained clinical remission should be tailored to these criteria.
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